Welcome to AtriAN
Mission & Vision
Resolving Atrial Fibrillation at its origin
A Disruptive Approach to Rhythm restoration
AtriAN’s Business Pathway
Robust and Innovative Intellectual Property (IP)
Funding in Place
First In Human (FIH) Trials
Pulsed Field Ablation (PFA)
GENTLE, NON-THERMAL ENERGY
Pulsed Field Cardioneuroablation
Selectively targets and disables the GPs
Gently spares the myocardium (heart muscle).
As a result, the other tissues, such as healthy heart muscle, are spared.
Unique, IP-Protected Catheters
AtriAN team members
US CEO Roles, R&D, Eng. Mfg,
20+ Yrs Experience
Barry O’Brien, PhD
R&D, Development, BSC
20+ Yrs Experience
Advant Med, 15+ Yrs Exp.
Medical Advisory Team
Mark Carlson, MD
Former Chief Medical Officer
St. Jude (Abbott)
Vivek Reddy, MD
Mt. Sinai, NY
Joris deGroot, MD
Samuel Asirvatham, MD
Former CEO Bardy Diagnostics,
Atlantic Bridge Ventures
Former CEO, Creganna
Mark Bruzzi, PhD
Former Pres. Of Abbott Vascular
Medtech Launch LLC
Former Dir. of Coronary Marketing, Abbott
Novel Percutaneous Epicardial Autonomic Modulation in the Canine for Atrial Fibrillation: Results of an Efficacy and Safety Study
M Madhavan, KL Venkatachalam, MJ Swale et al
Pacing Clin Electrophysiol 2016.
This was the first screening study at Mayo Clinic to assess the best energy source for ablation of ganglionated plexi, while minimizing myocardial damage. Following selection of pulsed field ablation (PFA) from the screening work, procedural feasibility was also demonstrated in both open-chest and sub-xiphoid models, using early prototype devices.
D Padmanabhan, N Naksuk, AK Killu et al
J Cardiovasc Electrophysiol 2019.
This study was performed using sub-xiphoid access with acute measurements showing that ganglionated plexi ablation produced an extension in the atrial effective refractory period (AERP). Extensive histology evaluations at four month follow-up demonstrated ablation of ganglia structures with sparing of the myocardium. The animals were resistant to AF induction at four months.
M van Zyl, M Khabsa, JA Tri et al
J Innov Cardiac Rhythm Manage 2022.
This open-chest study was performed as full system validation before progressing to first-in-human open-chest clinical trials. It’s utilized AtriAN’s cardiac-customized pulsed field generator and devices designed specifically for open-chest epicardial treatment. Acute extensions in atrial effective refractory period (AERP) were demonstrated as well as evidence of reversible electroporation in myocardial tissue.
Safety and Feasibility of Epicardial Percutaneous Access and Maneuverability With a Novel Ablation Catheter for the Treatment of Atrial Fibrillation in a Porcine Model
P Buszman, K Lukasik, S Deane et al
J Am Coll Cardiol 2021 (Supplement).
This was a first feasibility of epicardial access using the initial prototype of a next generation catheter system designed for sub-xiphoid access and with bipolar ablation capability. Access to the pericardial space was demonstrated with conventional needle technology and the catheter demonstrated promising tracking and navigation performance.
Establishing Irreversible Electroporation Electric Field Potential Threshold in A Suspension In Vitro Model for Cardiac and Neuronal Cells
S Avazzadeh, B O’Brien, K Coffey et al
Journal of Clinical Medicine 2021
This in-vitro cellular study explored the electroporation thresholds of neurons and cardiomyocytes in suspension. This is the first published data showing that the thresholds for both cell types are similar; the data for neuron cell bodies being much lower than published data on axons. This provides initial data towards understanding the mechanism of selective ablation of ganglionated plexi.
Establishing electroporation thresholds for targeted cell specific cardiac ablation in a 2D culture model
S Avazzadeh, MH Dehkordi, P Owens et al
J Cardiovasc Electrophysiol 2022.
This study of in-vitro electroporation assessed cultured layers of cardiomyocytes and neurons and showed that neurons have a slightly lower threshold compared to cardiomyocytes. In addition neurons showed continued cell death up to 24 hours after treatment, while cardiomyocytes trended towards low levels of recovery. This insight provides further understanding of how ganglionated plexi may be ablated and myocytes spared in an in vivo scenario.
Electric Field Models
A González-Suárez, RM Irastorza, S Deane et al.
Computer Methods and Programs in Biomedicine 2022.
This is a fundamental electric field model study aiming to demonstrate the applicability of a model geometry around the treatment zone in an epicardial configuration. This monopolar model showed how the peak electric field strengths are located very close to the catheter electrodes and drop off very rapidly beyond this. The field strength levels in adjacent organs were exceptionally low, verifying the absence of collateral tissue damaged observed in pre-clinical studies.
Pulsed Electric Field Ablation of Epicardial Autonomic Ganglia: Computer Analysis of Monopolar Electric Field across the Tissues Involved
Electric Field Models
A González-Suárez, B O’Brien, M O’Halloran et al
This electric field modelling study assessed the field strength distribution in the epicardial fat pads (where the ganglionated plexi are located) and the underlying myocardium, when monopolar pulses are applied. The field strength tends to concentrate within the fat layer, with a substantial drop off into the myocardium. This effect further explains the observed selectivity of ganglia ablation when the treatment is performed epicardially.
Get In Touch
Visit us in Galway
Unit 204 (Billing), H91W60E